Vasoflux, a new anticoagulant with a novel mechanism of action.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Circulation

• Publication date

  1999-02-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.99.5.682PMID 9950667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low molecular weight heparins

  2000cited by this paper
• Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.

  1998cited by this paper
• Low-molecular-weight heparins.

  1997cited by this paper
• An experimental model of human leukemic meningitis in the nude rat.

  1997cited by this paper
• Evidence for Allosteric Linkage between Exosites 1 and 2 of Thrombin*

  1997cited by this paper
• Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.

  1997cited by this paper
• A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.

  1996cited by this paper
• Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.

  1996cited by this paper
• The Effect of Fibrin Clots and Clot-Bound Thrombin on the Development of Platelet Procoagulant Activity

  1995cited by this paper
• A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.

  1995cited by this paper
• Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.

  1995cited by this paper
• Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction.

  1995cited by this paper
• Dermatan Sulfate Is a More Potent Inhibitor of Clot-bound Thrombin than Unfractionated and Low Molecular Weight Heparins

  1994cited by this paper
• The Influence of Fibrinogen and Fibrin on Thrombin Generation - Evidence for Feedback Activation of the Clotting System by Clot Bound Thrombin

  1994cited by this paper
• Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator.

  1994cited by this paper
• Importance of factor Xa in determining the procoagulant activity of whole-blood clots.

  1993cited by this paper
• Recombinant Hirudin in Patients With Chronic, Stable Coronary Artery Disease Safety, Half‐life, and Effect on Coagulation Parameters

  1993cited by this paper
• Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.

  1993cited by this paper
• Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins

  1993cited by this paper
• Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin.

  1993cited by this paper
• The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate

  1993cited by this paper
• A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture

  1992cited by this paper
• Reactivation of unstable angina after the discontinuation of heparin.

  1992cited by this paper
• Drug therapy : heparin

  1991cited by this paper
• Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.

  1991cited by this paper
• The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin.

  1990cited by this paper
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

  1990cited by this paper
• Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

  1989cited by this paper
• Protection of factor Xa from neutralization by the heparin-antithrombin complex.

  1983cited by this paper
• Activation of heparin cofactor II by dermatan sulfate.

  1983cited by this paper
• The binding of low molecular weight heparin to hemostatic enzymes.

  1980cited by this paper
• Phospholipid-binding properties of bovine factor V and factor Va.

  1979cited by this paper

• Investigations of the effectiveness of heparin variants as inhibitors of histones

  2022cites this paper
• Mechanistic Studies of DNase I Activity: Impact of Heparin Variants and PAD4

  2021cites this paper
• Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

  2020cites this paper
• Therapeutic monitoring of unfractionated heparin – trials and tribulations

  2017cites this paper
• Old and new applications of non-anticoagulant heparin.

  2016cites this paper
• Heparinoid hydrogels for cardiovascular tissue regeneration

  2015cites this paper
• COMBINED NMR/LC-MS APPROACH FOR STRUCTURAL CHARACTERIZATION OF HEPARINS AND NON-ANTICOAGULANT GLYCOL-SPLIT HEPARINS

  2014cites this paper
• Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides.

  2013cites this paper
• Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments

  2013cites this paper
• Recent advances in search of oral heparin therapeutics

  2012cites this paper
• Heparin Analogs Created by Sulfation of Alginates Using a Chemoenzymatic Strategy

  2012cites this paper
• Unconventional treatment options in severe asthma: an overivew.

  2011cites this paper
• NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities

  2010cites this paper
• Identification of diabetic nephropathy‐selective proteins in human plasma by multi‐lectin affinity chromatography and LC‐MS/MS

  2010cites this paper
• The anti-inflammatory effects of heparin and related compounds.

  2008cites this paper
• Practice Guidelines (8th Edition) Clinical of Chest Physicians Evidence-Based Parenteral Anticoagulants: American College

  2008cites this paper
• Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• A Systematic Review of Heparin to Treat Burn Injury

  2007cites this paper
• A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury

  2006cites this paper
• The Future of Anticoagulation

  2004cites this paper
• The Heparin Binding Properties of Heparin Cofactor II Suggest an Antithrombin-like Activation Mechanism*

  2004cites this paper
• Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• Novel Anticoagulants for the Prevention and Treatment of Venous Thromboembolism

  2003cites this paper
• Targeting thrombin--rational drug design from natural mechanisms.

  2003cites this paper
• Overview of anticoagulant drugs for the future.

  2002cites this paper
• Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin.

  2002cites this paper
• Antithrombin-Heparin Covalent Complex: A Possible Alternative to Heparin for Arterial Thrombosis Prevention

  2002cites this paper
• Molecular Basis for the Susceptibility of Fibrin-bound Thrombin to Inactivation by Heparin Cofactor II in the Presence of Dermatan Sulfate but Not Heparin*

  2001cites this paper
• Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).

  2001cites this paper
• Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase*

  2001cites this paper
• Are Infra-Inguinal Angioplasty and Surgery Comparable?

  2001cites this paper
• Drugs in Development: New Agents, New Classes, New Indications

  2000cites this paper
• Cardiopulmonary bypass in humans: bypassing unfractionated heparin.

  2000cites this paper
• Comparison of Heparin- and Dermatan Sulfate-mediated Catalysis of Thrombin Inactivation by Heparin Cofactor II*

  1999cites this paper
• Recent advances in cardiovascular pharmacology.

  1999cites this paper
• Nouveaux traitements antithrombotiques

  1999cites this paper
• Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

  1998cites this paper